SCHEMBL1007595

SCHEMBL1007595

O=C(Cl)CCCCCCCC=Cc1cncs1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.39
HDAC8 Q9BY41 6/20 0.39
HDAC3 O15379 5/20 0.39
HDAC2 Q92769 5/20 0.39
HDAC6 Q9UBN7 5/20 0.39
HDAC4 P56524 4/20 0.39
HDAC7 Q8WUI4 3/20 0.39
HDAC10 Q969S8 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
HDAC9 Q9UKV0 3/20 0.39
HDAC5 Q9UQL6 3/20 0.39
TBXAS1 P24557 3/20 0.38
NLRP3 Q96P20 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
FAAH O00519 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007594 1.00 HDAC1 (0.39) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL1008612 0.87 TBXAS1 (0.51) TBXAS1ALDH1A1TSHRFAAH
SCHEMBL1008613 0.87 TBXAS1 (0.51) TBXAS1ALDH1A1TSHRFAAH
SCHEMBL16266692 0.72 OXER1 (0.30)
SCHEMBL27602901 0.69 ALDH1A1 (0.48) ALDH1A1TSHRFAAH
SCHEMBL1007844 0.67 ALOX5 (0.47) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL1007845 0.67 ALOX5 (0.47) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL1008585 0.66 HDAC1 (0.46) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL1008586 0.66 HDAC1 (0.46) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL19361965 0.65 ALDH1A1 (0.54) ALDH1A1TSHRFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268606-B1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8344027-B2 4-dimethylaminobutyric acid derivatives HOFFMANN-LA ROCHE INC. (US) 2013-01-01 US disclosed
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES ANDJELKOVIC MIRJANA (CH) 2012-11-15 US disclosed
EP-2268606-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009132978-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 HDAC1 360/4885HDAC8 1043/4885HDAC3 523/4885
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 HDAC1 360/4885HDAC8 1043/4885HDAC3 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.